Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253902 · ClinicalTrials.gov registry record · Phase 4
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 4 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 164
- Enrollment target
- 2
- Study locations
NCT01253902 is a Phase 4 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Allergan. The registered enrollment target is 164 participants, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01253902, a Phase 4 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 164 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG bimatoprost ophthalmic solution 0.01%
- DRUG travoprost ophthalmic solution 0.004%
- DRUG latanoprost ophthalmic solution 0.005%
Study Locations (2)
Arkansas
- - Rogers
Alberta
- - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253902
The ClinicalTrials.gov registry entry for NCT01253902 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (40% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which bimatoprost ophthalmic solution 0.01% is the first listed.
NCT01253902 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arkansas, Alberta.
Frequently Asked Questions
What is clinical trial NCT01253902 about?
NCT01253902 is a clinical study titled "Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension". This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have ...
What is the current status of trial NCT01253902?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 164 participants. The study started on 2010-12. Estimated completion is 2011-10.
What conditions does trial NCT01253902 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT01253902?
The interventions under investigation include: bimatoprost ophthalmic solution 0.01% (DRUG), travoprost ophthalmic solution 0.004% (DRUG), latanoprost ophthalmic solution 0.005% (DRUG).
Who is sponsoring clinical trial NCT01253902?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01253902 being conducted?
This trial has 2 study locations across Arkansas, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
-
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
COMPLETED · Phase 4
-
DSLT for Reducing Medication in Glaucoma
RECRUITING
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.